International Society for Quality of Life Research commentary on the US Food and Drug Administration draft guidance for industry on core patient-reported outcomes in cancer clinical trials

In June 2021, the US Food and Drug Administration (FDA) released a draft guidance for industry on core patient-reported outcomes (PROs) and related considerations for instrument selection and trial design in registrational cancer clinical trials, building on prior communications about the use of PRO...

Descripción completa

Detalles Bibliográficos
Autores principales: Brady, Keri J. S., Peipert, John Devin, Atkinson, Thomas M., Pompili, Cecilia, Pinto, Monica, Shaw, James W., Roydhouse, Jessica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202747/
https://www.ncbi.nlm.nih.gov/pubmed/37217665
http://dx.doi.org/10.1007/s11136-023-03396-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202747/
https://www.ncbi.nlm.nih.gov/pubmed/37217665
http://dx.doi.org/10.1007/s11136-023-03396-z

Ejemplares similares